Top Injectable Manufacturer in Sierra Leone – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 3 days ago
- 11 min read
Last Updated: August 23, 2026
TL;DR: Sierra Leone's medicines regulator is the Pharmacy Board of Sierra Leone (PBSL), re-established under the Pharmacy and Drugs Act 2001, ISO 9001:2015 certified since 2019 and operating a complete guideline suite from PBSL-GL-001 to PBSL-GL-040 published in 2025. A foreign manufacturer must appoint a locally incorporated agent licensed by PBSL to import, file a Common Technical Document dossier aligned to WHO prequalification and ICH format in English, and provide a valid WHO or EU GMP certificate together with a WHO-format Certificate of Pharmaceutical Product naming Sierra Leone. PBSL inspects foreign sterile sites for three to five days before initial approval and once every three years thereafter, requiring a score of at least 70% with zero critical observations, at a published FY 2026 fee of US$10,000, with new generic product registration at US$550. Public-sector medicines are procured by the National Medical Supplies Agency under the NMSA Act 2017, alongside the Free Health Care Initiative and donor channels including a US$136.2 million Global Fund grant running to June 2027. With no verified domestic pharmaceutical manufacturing, essentially every vial and ampoule used in the country is imported. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 lines, exporting to 30+ countries, and generating Zone IVb stability data at 30°C/75% RH — the exact condition PBSL requires.
Key Takeaways
The Pharmacy Board of Sierra Leone (PBSL), established under the Pharmacy and Drugs Act 2001 and reporting to the Ministry of Health and Sanitation, has held ISO 9001:2015 certification since 2019, runs its own National Pharmaceutical Quality Control Laboratory, and published a full numbered guideline suite (PBSL-GL-001 to PBSL-GL-040) in 2025; it is one of only seven West African regulators participating in ECOWAS/WAHO joint assessment.
The pathway is specific: a locally incorporated agent holding a PBSL import and wholesale licence, a CTD dossier in English aligned to WHO prequalification and ICH format, a valid WHO or EU GMP certificate plus a WHO-format CPP naming Sierra Leone, and a three-to-five-day on-site GMP inspection for sterile products scoring at least 70% with zero critical observations — US$10,000 every three years, with generic registration at US$550 for FY 2026.
Demand is overwhelmingly parenteral: malaria incidence was 293 per 1,000 population at risk in 2023 with parenteral artesunate first-line for severe cases, maternal mortality was 354 per 100,000 live births in 2023, under-five mortality 104.7 per 1,000, and the country has roughly 0.15 specialist surgeons, anaesthetists and obstetricians per 100,000 people.
Farbe Firma Pvt Ltd manufactures 100+ sterile injectables under WHO-GMP in Gujarat, India on ISO Class 5 aseptic lines, exports to 30+ countries, and generates ICH Q1A(R2) Zone IVb stability at 30°C/75% RH — matching PBSL's published requirement — with English labelling, INN presentation and remaining-shelf-life rules built into the supply plan.
Introduction: Why an Injectable Manufacturer in Sierra Leone Must Meet Global Standards
Sierra Leone had an estimated 8,819,794 people in mid-2025, and almost none of the medicines they use are made at home. A 2022 review in the Journal of Pharmaceutical Policy and Practice, co-authored with the Pharmaceutical Society of Sierra Leone and citing the WAHO/UNIDO GMP roadmap for the country, recorded that Sierra Leone had no operating pharmaceutical manufacturing company — a single plant had closed roughly two decades earlier, and no roadmap to replace it was then in progress. Four years on there is still no verified domestic sterile injectable capacity. Every vial of artesunate, every ampoule of oxytocin and every gram of injectable antibiotic used in a Sierra Leonean hospital arrives through the port at Freetown or the airport at Lungi. That makes the choice of injectable manufacturer in Sierra Leone a public-health decision as much as a commercial one, and it explains why the regulator's documentary requirements are as detailed as they are.
Farbe Firma Pvt Ltd, a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, is built for exactly this kind of market. The company fills more than 100 sterile injectable presentations — ampoules, vials, lyophilised powders for reconstitution and small-volume parenterals — on ISO Class 5 aseptic lines and exports to more than 30 countries, many of them tropical, high-humidity markets whose regulators demand the same Zone IVb stability evidence the Pharmacy Board of Sierra Leone requires. The relevant capability is not simply making the product. It is producing a dossier, a stability package, an English label with the INN correctly presented and a GMP history that will withstand a PBSL inspection and, where donor money is involved, a further quality gate layered on top of it.
What Sets a World-Class Injectable Manufacturer in Sierra Leone Apart
The Pharmacy Board of Sierra Leone (PBSL), re-established under the Pharmacy and Drugs Act 2001 and reporting to the Ministry of Health and Sanitation, is the national medicines regulatory authority, and it has professionalised visibly. PBSL has held ISO 9001:2015 certification since 2019, runs its own National Pharmaceutical Quality Control Laboratory, and in 2025 published a complete numbered guideline suite running from PBSL-GL-001 to PBSL-GL-040 covering registration, CTD submission, GMP inspection, importation and clearance, good distribution and storage practice, stability, bioequivalence and emergency use authorisation. Sierra Leone does not yet appear on WHO's list of authorities benchmarked at Maturity Level 3, but it is one of only seven West African regulators taking part in joint assessment sessions under the ECOWAS/WAHO West African Medicines Regulatory Harmonisation initiative, and it maintains a recognition memorandum with Ghana's Food and Drugs Authority. A foreign manufacturer cannot file directly: PBSL-GL-025 requires a representative that is a company incorporated in Sierra Leone, authorised by PBSL to import and holding a wholesale licence.
The technical requirements are specific and published. Dossiers follow the Common Technical Document, explicitly aligned to WHO prequalification guidance and ICH format, in English, supported by a valid WHO or EU GMP certificate and a WHO-format Certificate of Pharmaceutical Product issued in the name of Sierra Leone or naming it among importing countries. PBSL inspects foreign manufacturers before initial approval and once every three years, applying WHO, PIC/S and EU cGMP standards; for non-biological sterile products the on-site inspection runs three to five days with at least two qualified inspectors, one experienced in sterile manufacture, and the site must score at least 70% overall and on each production line with zero critical observations. Published FY 2026 fees are US$10,000 for an international GMP inspection every three years, US$550 for a new generic registration, US$600 branded and US$500 for quality analysis. Importation then runs through three separate permissions — an importer licence, a per-shipment import permit and a clearance permit applied for at least 21 days before the consignment arrives — with entry restricted to Queen Elizabeth II Quay and Lungi International Airport, and a requirement that consignments retain at least 60% of shelf life where total shelf life exceeds 24 months, or at least 80% where it does not.
Quality Systems Behind Every Batch We Ship to Sierra Leone
Every batch destined for Sierra Leone passes the same analytical panel Farbe Firma applies to all markets. Identity and assay run on stability-indicating HPLC, with GC for residual solvents and Karl Fischer titration for water content in lyophilised vials. Sterility testing, bacterial endotoxin testing by LAL, sub-visible particulate counts, pH, osmolality, extractable volume and container-closure integrity are performed on every sterile lot. Aseptic fill-finish takes place under ISO Class 5 unidirectional airflow with continuous viable and non-viable environmental monitoring, routine media fills and documented operator qualification. Specifications are written against USP, BP, IP or EP monographs as required, and certificates of analysis, batch manufacturing records, the Site Master File and the post-marketing surveillance plan are assembled in the form PBSL asks for rather than reformatted late in the process. Registration samples are drawn from a single batch with at least two-thirds of shelf life remaining, in the quantities PBSL specifies — including 50 vials per strength for dry powders for reconstitution.
Stability is the point where many dossiers fail in West Africa, and it is where a manufacturer's export history shows. PBSL requires real-time studies at 30°C ± 2 and 75% RH with accelerated studies at 40°C ± 2 and 75% RH — Zone IVb, the hottest and most humid ICH classification — on three batches in the marketed container-closure system, with results presented in both tabular and graphical form. Farbe Firma generates Zone IVb data as standard under ICH Q1A(R2), with ICH Q1B photostability where the molecule demands it, because the majority of its export markets sit in that zone. Combined with cold-chain fragility that PBSL itself acknowledges — its import guideline gives port inspectors power to release perishables such as vaccines, immunoglobulins and oxytocin outside normal business hours, and to move consignments that have begun losing cold chain to the importer's storage facility to prevent further deterioration — heat-stable formulations, robust container-closure systems and generous remaining shelf life become competitive advantages rather than marketing claims.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Sierra Leone for Global Buyers
The clinical demand is overwhelmingly parenteral. Malaria incidence stood at 293 cases per 1,000 population at risk in 2023 with the entire population at risk, and malaria accounts for roughly 37.6% of hospital admissions and 38% of under-five deaths. WHO's malaria guidelines updated in August 2025 direct that severe malaria in adults and children — including infants, pregnant women in all trimesters and lactating women — be treated with intravenous or intramuscular artesunate for at least 24 hours and until oral therapy is tolerated, and Sierra Leone's national policy makes parenteral artesunate first-line for severe cases. Maternal mortality fell from 443 per 100,000 live births in 2020 to 354 in 2023, the fastest reduction in eight years but still among the world's highest, sustaining demand for oxytocin, magnesium sulfate and tranexamic acid. Under-five mortality is 104.7 per 1,000 live births, with pneumonia at 20% of deaths in children aged one to 59 months and neonatal infections prominent among newborn deaths, driving injectable antibiotic use. Tuberculosis incidence was 273 per 100,000 in 2023 and HIV prevalence 1.7%. On top of this, an mpox outbreak declared a national emergency in January 2025 had exceeded 5,400 cases and 60 deaths by November 2025, with international medical teams deployed specifically for surgical management of complex cases.
Sierra Leone's surgical workforce makes formulation robustness a clinical safety issue rather than a matter of convenience. The country has roughly 0.15 specialist surgeons, anaesthetists and obstetricians per 100,000 people — under 1% of the recommended level — with published estimates of about five general surgeons for a population above eight million, and surgical volume near 400 procedures per 100,000, less than a tenth of the expected rate. Much anaesthesia is delivered by nurse anaesthetists rather than specialist anaesthetists. In that setting, clear English labelling with the INN printed immediately below the brand name in equal print size, batch number and expiry printed onto the pack rather than applied on an adhesive label, unambiguous strength declarations and simple, forgiving presentations reduce the chance of error at the bedside. Farbe Firma also works as a CDMO and CMO partner, offering private-label and third-party manufacturing for importers, distributors and NGOs that want their own brand on a WHO-GMP produced injectable, with artwork, pack inserts and dossier support prepared to PBSL's published requirements rather than adapted afterwards.
Buyers should understand how the money actually flows, because it determines which door a supplier can enter. The National Medical Supplies Agency, created by the NMSA Act 2017 and fully operational since 2019, holds exclusive responsibility for procuring, warehousing and distributing drugs and medical supplies for all public institutions, and publishes tender notices and contract awards; it works alongside the Free Health Care Initiative launched in April 2010 for children under five and pregnant and lactating women. External financing is decisive: World Bank data for 2022 put external sources at about 30% of current health expenditure against roughly 14% from domestic government, with out-of-pocket spending at 55%, and the Global Fund approved US$136.2 million for Sierra Leone for the period July 2024 to June 2027. That donor money carries its own quality gate — Global Fund procurement generally requires WHO prequalification, stringent regulatory authority or WHO-Listed Authority approval, or clearance through the Expert Review Panel — so PBSL registration alone opens the private, wholesale and government-budget channels, while donor-funded volume requires that additional step. It is an honest distinction worth stating plainly, particularly in a market where PBSL has spent 2025 and 2026 incinerating counterfeit and substandard stock in Kenema and at Lungi and acting against illegally imported opioids. Quality documentation is not a formality here; it is the whole argument.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Sierra Leone?
Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, producing more than 100 injectable presentations — ampoules, vials, lyophilised powders for reconstitution and small-volume parenterals — on ISO Class 5 aseptic fill-finish lines and exporting to more than 30 countries. For Sierra Leone the company supplies a WHO-format Certificate of Pharmaceutical Product naming the country, a valid WHO-GMP certificate, a Site Master File, batch manufacturing records, certificates of analysis written to USP, BP, IP or EP monographs, and CTD dossiers in English aligned to WHO prequalification and ICH format, together with the registration sample quantities PBSL specifies.
How does a foreign injectable manufacturer register a product with the Pharmacy Board of Sierra Leone?
A foreign manufacturer cannot file directly. PBSL-GL-025 requires the appointment of a local representative that is a company incorporated in Sierra Leone, authorised by PBSL to import pharmaceutical products and holding a wholesale licence, and the application is filed through that agent. The submission is a Common Technical Document dossier in English with a WHO or EU GMP certificate and a WHO-format CPP naming Sierra Leone. PBSL's guidelines state a decision within three months of a complete submission with samples, with provisional registration for 12 months for new products and three-year validity thereafter; in practice the critical path for a new site is the GMP inspection cycle rather than the dossier review.
Does the Pharmacy Board of Sierra Leone accept a WHO-GMP certificate and a CPP?
Yes. PBSL's registration guidance explicitly names a valid World Health Organization or European Union Certificate of Good Manufacturing Practice, and requires a valid Certificate of Pharmaceutical Product from the country of origin issued under the WHO certification scheme, either in the name of Sierra Leone or with Sierra Leone included in the list of importing countries. PBSL also operates reliance provisions under PBSL-GL-011, under which a cGMP certificate or manufacturing licence from a strong drug regulatory authority, a Site Master File approved by such an authority and a GMP inspection report from a strong international regulator may be accepted in lieu of an immediate on-site inspection.
What stability data does Sierra Leone require for injectable products?
PBSL requires Zone IVb conditions: real-time stability studies at 30°C ± 2 and 75% RH, with accelerated studies at 40°C ± 2 and 75% RH, conducted on three batches in the marketed container-closure system, with data for each presentation and results presented in both tabular and graphical form. Real-time data is required for all biologicals. Farbe Firma generates Zone IVb data as standard under ICH Q1A(R2), with ICH Q1B photostability where the molecule requires it, so a dossier does not have to wait on a fresh study. Consignments must also retain at least 60% of shelf life at import where total shelf life exceeds 24 months, or at least 80% where it does not.
Can Farbe Firma supply injectables for NMSA tenders and donor-funded programmes in Sierra Leone?
For NMSA tenders and the government-budget, private and wholesale channels, PBSL product registration and a licensed local importer are the operative requirements. Donor-funded volume is a separate question and should be planned for honestly: Global Fund procurement generally requires WHO prequalification, approval by a stringent regulatory authority or WHO-Listed Authority, or clearance through the WHO-hosted Expert Review Panel, and UNICEF and other pooled procurers apply comparable gates. Farbe Firma works with importers, distributors and NGOs on dossier preparation, CPP support, artwork and supply planning for both routes, and is candid about which molecules are ready for which channel.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments